Enduring Material

• The Colorado Medical Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Colorado Medical Society designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Course Overview

Hepatorenal syndrome is one of many potential causes of acute kidney injury in patients with liver disease. HRS represents the end-stage of a sequence of reductions in kidney perfusion induced by increasingly severe hepatic injury. HRS is a diagnosis of exclusion and generally has a poor prognosis. A cirrhotic liver disrupts fluid management. Decreased liver function combines with portal hypertension to cause ascites symptoms. Portal hypertension causes fluid to leak from the veins into the belly and collect there. To manage the ascites, patients need to have large volumes of fluid removed or put other organs at risk. Regrettably, not enough clinicians have an adequate understanding of the disease progression, appropriate diagnostic tests and appropriate treatment regimes. This short, but highly focused, seminar will provide that information.

Topics to be covered in this interactive seminar include:

The causes, symptoms, and treatment for ascites
Life-threatening dangers of cirrhosis and the importance of fluid management
Employing realistic sodium reduction approaches for patients with mild ascites
The benefits vs risks of a TIPS procedure
Differentiate between Type 1 and Type 2 HRS
How Hepatorenal Syndrome advances and can lead to renal failure
Investigate the benefits and risks of various HRS treatment approaches
Advising patients on the most efficacious therapies for Hepatorenal Syndrome to minimize further damage to the liver and kidneys

CMS staff and planners of this activity have no relevant financial relationships with ACCME defined ineligible companies to disclose.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

0 %

50 %

2/11/2025